Ind-Swift Laboratories

Ind-Swift Group is a leading pharmaceutical export company supplying quality generic and branded medicines to 85+ global markets with WHO-GMP standards.

Portfolios Archive - Ind-Swift Group

Careers Archive - Ind-Swift Group

Ind-Swift Group provides career opportunities in pharmaceutical innovation, research, and global healthcare solutions.

Ind-Swift Group offers career opportunities in pharmaceutical research, quality, and healthcare innovation.

Ind-Swift Group is a pharmaceutical company in India with global operations and innovative healthcare solutions.

Ind-Swift Group ensures pharmaceutical products meet global safety, efficacy, and compliance standards.

Ind-Swift Group is a leading pharma manufacturing company offering quality medicines, APIs, formulations, and healthcare solutions for a healthier world.

Reimaging Pharma.Reshaping Tomorrow.

Ind-Swift Laboratories Ltd announces a significant increase in profit after tax (PAT) for its second-quarter 2027 earnings. The company highlights strong financial performance during the quarter, though specific figures or growth drivers are not detailed in the report. Investors and analysts monitor the results for insights into the pharmaceutical company’s operational health.

Nov 2026Yahoo FinanceNews article

Ind-Swift Laboratories’ stock price jumps 18.19% to ₹280.40 following an 183% year-over-year rise in consolidated profit after tax (PAT) for Q1, ending June 30, 2026. The company’s financial results reflect a significant improvement in profitability for the quarter. Investors react positively to the reported growth in earnings.

Aug 2026business-standard.comNews article

Ind-Swift Laboratories Ltd updates its **Code of Fair Disclosure** and **Insider Trading Policy** to comply with SEBI’s 2015 regulations. The revised rules require **pre-clearance for trades**, enforce **trading windows**, and mandate disclosure for transactions by designated persons and their relatives. The Board approved the amendment on **June 22, 2026**, via circular resolution.

Jun 2026scanx.tradeNews article

Ind-Swift Laboratories approves four special resolutions via postal ballot, including leadership changes. The company reassigns Sh. N.R. Munjal’s designation, appoints Himanshu Jain and Sahil Munjal as Managing Directors, and approves remuneration for Whole-Time Director Rishav Mehta. The vote involved 36,164,227 shares, or 41.65% of outstanding shares, with the ballot closing on April 30, 2026.

May 2026scanx.tradeNews article